Vertex Pharmaceuticals (VRTX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

VRTX Vertex Pharmaceuticals

Watchlist

397.270
+0.630+0.16%

Close Dec 20 16:00 ET

394.850
-2.420-0.61%

Post 20:01 ET

102.31BMarket Cap-209.09P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Seeking AlphaDec 21 10:58 ET
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $418 to $535
Moomoo NewsDec 21 08:00 ET · Ratings
Vertex Pharmaceuticals Price Target Lowered to $441 From $506 at Bernstein
Yahoo FinanceDec 21 07:30 ET
Express News | Vertex Pharmaceuticals-Established Wholesale Acquisition Cost for Alyftrek in United States of $370,269 on Annual Basis ($28,404 per 28-Day Pack)
ReutersDec 20 16:12 ET
Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
WSJDec 20 16:00 ET
Express News | Vertex Pharmaceuticals Inc: Alyftrek(™) Is Approved for Patients 6 Years and Older With at Least One Responsive Mutation
ReutersDec 20 15:48 ET

Comments

Lnova

Dec 19 18:23

$Vertex Pharmaceuticals (VRTX.US)$
nfa

Vertex Stock Plunges 13% Over Pain Drug's Disappointing Study Results

Lnova

Dec 19 18:19

“SiteOne Therapeutics Announces a $100 Million Series C Financing to Advance Selective Ion Channel Modulators as Non-Opioid Treatments for Pain.
SiteOne’s efforts in non-opioid pain management put it in a unique position relative to Vertex Pharmaceuticals, a major player in the field known for its successful development of cystic fibrosis treatments. Vertex has also been working on non-opioid pain drugs, specifically targeting the NaV1.8 sodium channel, a focal point shared by SiteOne’s lead pro...

SiteOne Therapeutics Announces a $100 Million Series C Financing to Advance Selective Ion Channel Modulators as Non-Opioid Treatments for Pain

Kevin Travers

Nov 15 15:20

Columns Market Falls to End All-Time High Week | Wall Street Today

In the end, a week that starts with an all-time high for the S&P 500, Dow Jones, and Nasdaq 100, ended with equities lower.
At 4:02 p.m. ET, the three indices closed lower. The $Dow Jones Industrial Average (.DJI.US)$ was off 0.70%, losing 300 points. The $S&P 500 Index (.SPX.US)$ was down 1.32% and the $Nasdaq Composite Index (.IXIC.US)$ was off 2.24%.
MACRO
In macro, core retail sales grew by 0.1% month over month, lower than estimated. ...

Live Stock Financial Podcast. What are you watching on the market?

Kevin Travers

Nov 15 10:12

Columns Market Falls Friday on Earnings | Live Stock

You will not get through the trading day without the news and animal spirits guiding the market. It is finally Friday, November 15th.
My name is Kevin Travers and the market is falling today- here is why.
$Alibaba (BABA.US)$ shares declined after a report from the firm Friday morning that it was facing a consumer demand slump, even though its AI cloud business grew 7% to $4.2B in its second fiscal quarter.
$Applied Materials (AMAT.US)$ fell 8% after r...

Powell says no hurry for Fed rate cuts, how will you adjust your investment strategy?

Nnuge

Nov 11 03:16

Golden Cross

The indication of a golden cross is usually a strong buying signal. I like that Vertex is in the late stages of developing a cure for diabetes!

Paper Trading Competition: Share your P/L orders and elevate your trading skills

Heat List

Overall

No Data

Investment Theme

Gene Editing

Intraday+0.52%